Kala Pharmaceuticals, Inc.(KALA), is a biopharmaceutical corporation located in Watertown, Massachusetts which specializes in the research, development, and commercialization of therapies using its proprietary formulation technology platform. Founded in 2009, the company is dedicated to advancing the treatment of eye diseases.
The company’s main product is Inveltys, which is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery. Moreover, it has also developed a product known as Eysuvis, for the short-term treatment of the signs and symptoms of dry eye disease, which was approved by the FDA in October 2020. These treatments are designed to enhance penetration into the eye's tear film, aiming to provide relief to patients suffering from eye diseases.
Kala’s innovative drug delivery platform, known as AMPPLIFY, uses nanoparticle technology. This technology maximizes the potency and duration of therapeutic effect. The technology was designed to address the major challenge of ocular drug delivery, which is getting sufficient quantities of the medicine across the eye's tear film to reach the target tissue.
Kala Pharmaceuticals was initially a spinoff from renowned Massachusetts Institute of Technology (MIT). The company’s evolution has involved a series of successful funding rounds, with an eventual Initial Public Offering (IPO) in July 2017, providing a range of funding to fuel their research and product development programs.
The management team at Kala Pharmaceuticals is composed of healthcare industry professionals with extensive expertise in the pharmaceutical and optometry industry. The goal of the company is to utilize its proprietary technology to improve both the potency and the frequency of treatment required, offering promising advances for unmet medical needs.
In the future, Kala Pharmaceuticals intends to apply the AMPPLIFY Drug Delivery Technology to a range of other ocular diseases and conditions beyond dry eye and post-operative inflammation. Despite being a relatively young establishment in the pharmaceutical industry, Kala Pharmaceuticals, Inc. continues to make strides in the research and development of innovative solutions for eye diseases, thereby positively impacting the quality of life for patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
KALA Bio (NASDAQ: KALA) shares surged 57.10% after hours due to the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The proposed acquisition, valued at approximately $15 million, aims to add an established, revenue-generating platform to KALA's operating business, with closing targeted for late 2026 or early 2027. Despite the recent surge, KALA Bio's shares have fallen significantly over the past year.
KALA Bio, Inc. has signed a non-binding Letter of Intent to acquire a privately held, U.S.-based management services organization supporting a telehealth platform for approximately $15 million in cash and stock. The target platform, founded in 2023, has generated $48 million in sales, served over 90,000 clients, and focuses on health and wellness therapies including GLP-1 weight management, hormone health, longevity, and sexual wellness across all 50 states. This acquisition aims to add an established, revenue-generating platform to KALA Bio's business and expand its direct-to-consumer preventative care initiatives.